Sionna’s cystic fibrosis failure is a windfall for Vertex’s blockbuster franchise

A surprise flop in Phase 2a cystic fibrosis trial sent Sionna’s shares plummeting, but for Vertex, the news reinforced its standard-of-care standing with highly successful drugs like Trikafta.